^
    Back
    Association details:
    Biomarker:CXCR4 mutation
    Cancer:Waldenstrom Macroglobulinemia
    Drug:ibrutinib (BTK inhibitor) +
    ulocuplumab (BMS-936564) (CXCR4 antagonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Blood
    Title:

    Phase I study of Ibrutinib and the CXCR4 antagonist Ulocuplumab in CXCR4 mutated Waldenstrom Macroglobulinemia

    Published date:
    07/21/2021
    Excerpt:
    Phase I trial of the CXCR4-antagonist ulocuplumab with ibrutinib in this first-ever study to target CXCR4Mut in WM...The study demonstrates the feasibility of combining a CXCR4-antagonist with ibrutinib, and provides support for the development of CXCR4-antagonists for CXCR4Mut WM.
    DOI:
    10.1182/blood.2021012953
    Trial ID:
    NCT03225716